George Nemeth, MD, PhD has been the Chief Medical Officer for Gedeon Richter Plc. since 2002. He is responsible for leading Gedeon Richterís Medical Division, which includes chairing global clinical research, development and strategy teams; managing medical-regulatory-marketing issues and supervising pharmocovigilance activities. He began his carrier at the Medical School of Debrecen University, Department of Neurology and Psychiatry. Later on, he worked as a fellow of Alexander von Humboldt Foundation at the Department of Pathochemistry and General Neurochemistry, University of Heidelberg, Germany. Afterwards he had different fellowships at the Karolinska Institute in Stockholm, Sweden and at New York University Medical Center in New York, USA at the same time. He continued his professional career as a clinical researcher at Knoll AG, Department of CNS R&D, where later, he took over the responsibility as Global Strategic Director for world-wide clinical and regulatory activities, launching among others two new chemical entities. His main activities were international leader in the clinical development of drug candidates for the treatment of stroke; Parkinson's disease, epilepsy, major depression, schizophrenia, obesity and other non-CNS indications.
His research interest has extended to CNS clinical developments and personalized medicine. One of the success stories under his clinical leadership at Gedeon Richter was that a pioneering antipsychoticum (cariprazine) was approved by the FDA. In the meantime, he succeeded in verifying the efficiency of cariprazine in a niche indication (predominantly negative symptoms of schizophrenia) which was previously lacking therapeutic possibilities. Thus, he instituted and led the clinical developments of a first-in-class drug by using stratification approach. Owing to his comprehensive science operation, he is an active member of umpteen societies including Hungarian, European and American societies. He is committed to personalized medicine. He has been the President of Hungarian Personalized Medicine Society since its foundation (2010).